CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NVDA
9. FDXF
10. RKLB

Go back to CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
(NASDAQ: CERO) Delayed: 0.10 --0 (-0%)
Previous Close $0.10    52 Week High $ 
Open $0.10    52 Week Low $ 
Day High $0.10    P/E N/A 
Day Low $0.10    EPS $ 
Volume 800,331